{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-059164","form_type":"8-K","ticker":"HYPD","cik":"0001682639","company_name":"HYPERION DEFI, INC.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.026985+00:00","generated_at":"2026-06-15T04:18:27.405587+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Eyenovia Q1 net loss $5.7M; FDA approves Mydcombi for mydriasis","bullets":["FDA approved Mydcombi (tropicamide/phenylephrine) for mydriasis, first product using Optejet delivery system.","Received FDA feedback on Microline presbyopia candidate providing clear and efficient path forward.","Entered co-development agreement with Formosa Pharmaceuticals to combine Optejet with APNT nanoparticle platform.","Q1 net loss $5.7M ($0.15/share) vs $7.3M ($0.24/share) in Q1 2022; operating expenses down to $5.5M.","Cash and equivalents $18.5M at March 31, 2023; additional $5M available on Avenue Capital credit facility."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-059164","json":"https://secwatch.observer/filing/0001104659-23-059164.json","markdown":"https://secwatch.observer/filing/0001104659-23-059164.md","text":"https://secwatch.observer/filing/0001104659-23-059164.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682639/000110465923059164/0001104659-23-059164-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682639/000110465923059164/tm2315261d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:18:27.405587+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"111980ff98b5dff0650440839cb116defe8ed997","claim":"HYPERION DEFI, INC. reported first quarter ended March 31, 2023 results: net income $(5.7) million, EPS $(0.15) per share.","evidence_excerpt":"For the first quarter of 2023, net loss was approximately $(5.7) million, or $(0.15) per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1682639/000110465923059164/0001104659-23-059164-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"$(5.7) million"},{"label":"EPS","value":"$(0.15) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}